WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering

bioAffinity Technologies, Inc. has announced the pricing of a public offering of securities, aiming to raise approximately $3.2 million in gross proceeds. The offering, which consists of 4,000,000 shares of common stock priced at $0.80 per share, is expected to close on or about June 18, 2026. WallachBeth Capital, LLC serves as the sole placement agent for this transaction.

bioAffinity Technologies, based in Jersey City, New Jersey, is focused on developing noninvasive tests for the early detection of lung cancer and other lung diseases. The company's innovative approach addresses a significant need in the healthcare sector, particularly as lung cancer remains one of the leading causes of cancer-related deaths globally. The funds raised from this offering are likely to support the advancement of bioAffinity's product pipeline and enhance its market position in the competitive biotechnology landscape.

The offering structure includes the option for investors to purchase pre-funded warrants in lieu of common stock, providing flexibility for investors while ensuring the company can meet its capital requirements. Each pre-funded warrant will be immediately exercisable for one share of common stock, which may appeal to institutional investors looking for immediate equity exposure. The strategic rationale behind this offering aligns with bioAffinity's goal of expanding its operational capabilities and accelerating its research and development efforts.

The biotechnology sector continues to experience robust interest from investors, driven by advancements in medical technology and increasing demand for innovative healthcare solutions. As companies like bioAffinity Technologies pursue funding to enhance their product offerings, the overall market dynamics are influenced by both the competitive landscape and regulatory considerations. The successful completion of this offering could serve as a positive indicator for similar companies seeking to access capital markets.

In conclusion, the $3.2 million public offering by bioAffinity Technologies underscores the ongoing trend of biotechnology firms leveraging public markets to fund growth initiatives. As the sector evolves, continued investor interest may lead to more fundraising activities, particularly for companies focusing on critical health challenges such as early cancer detection. The implications of this transaction may resonate across the industry, potentially paving the way for further investments in innovative healthcare solutions.